Member Info for Inphobe

BRH is an entirely different type of co, and I would note that the directors there are not at all averse to selling their holdings also when it suits. It has dropped this year from a spike of over 120 to its current value of 26.75

It is quiet Guy and we don't know exactly what we'll get when (especially in regard to BC!) but we do know at least that the AIHL is awaiting release with Inspiration Healthcare and that the Covid PoC is with a PHE lab (and other bits of info on HCV and Military), so whilst we don't know exactly what's going on right now with all products that's not to say we don't know anything (I'm not going to repost the list I'm keeping because of the amount of ranting that engendered lady time, but it's there!)

Still on the list (under manufacturer notifications here https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/notifications-and-emergency-use-authorizations-faqs-testing-sars-cov-2 )

Or it was just cautionary, possibly on the advice of the nomad. Too many conspiracies here. But agree, it's deflated due to lack of news with bored/fearful investors selling low.

I believe she is saying they often do in practice

We're in conspiracy land now. Get a grip. It's just quiet and were waiting on news. The company are usually quiet on comms as we all know.

This is not a distressed co. It is debt free, in partnerships with Danaher grp co's. With products in PHE framework. UNICEF arrangement. In US DoD budget. Etc. About to release 2 more assays.

PIs just cannot cope without tweets. The partners in place will sell.

Lol

I think the current funds take the co up to roughly end of year if calculation done at time of last presentation still holds? Have to revisit but as far as I know Walbrook said that the talk of placing was unfounded fairly recently? Unfortunately silence from the company is rife breeding ground for rumour, but I'm expecting sales news. Jmo, but if you're going to talk about placings also bear in mind that this is now commercial stage and debt financing is probably cheaper for the co to arrange than placing if needed. Ymmv

ncyt down again a4uk? Also with the name calling of the ceo, grow up. Thought you made an amusing post the other day, but I suspect it was a one off. If you're going to troll at least do it with humour. You sound cross, and I know you're not invested here. I won't list again what the co has actually done this year again or that this is worth waiting for news on any one of the currently placed products, because those who are invested here know this and it's why they've stayed invested.

You've made many predictions before MyLuck, on this and other boards. And your crystal ball appears to be exceptionally unreliable. Whilst many things are possible, the future is unclear unlike your motives.

I dream of the day this board is free from mendacious drivel

A lot of tripe, fud, and low predictions (we're already at low mcap) being thrown at this as usual by the same old posters. The position of the products, however, is by my understanding as follows (and if the usual suspects are going to repeat themselves ad nauseam then I may as well repeat something useful). Corrections/additions welcome. Those who don't like it know where they can stick it.

Products/status

1/ AIHL due final release with distribution partner Inspiration Healthcare. CE marked; in PHE framework; NHS tested (2 NHS hospitals); unique; antibiotic use in infants guidelines updated to recommend testing; long term market anticipate primarily in 'developed' regions

2/ Cov96 kit being marketed in US and Europe (& elsewhere?) by Beckman Coulter and in India by Divoc. In PHE framework; CE marked in EU; ICMR approved and licenced for import in India; other approvals inc afaik South Africa, Malaysia, Thailand; still awaiting EUA in US; can currently be sold in US to CLIA certified labs; negotiations with an EU ministry of health still ongoing as far as we are aware; long term market clinical PCR Covid testing; detects variants, surveillance details here https://www.genedrive.com/assays/96-sars-cov2-variants.php

3/ HCV PoC with distributor Sysmex. In PHE framework; CE marked; trialled in Georgia and Cameroon by FIND; WHO pre-qualified, "eligible to participate in the procurement processes of UN agencies"; appears to have been taken up in a UNICEF supply division long term arrangement award March '21, possible NDA await confirmation; long term market UN/NGO priority, decentralised testing in the type of areas they're likely to use, use in for ex prison populations, surgeries, clinics. Also see https://www.finddx.org/

According to 350Dx article linked below "sales have resumed".

4/ Covid PoC now working. Currently being assessed in a Public Health England lab prior to CE marking; detects variants; long term market accurate clinical testing for Covid in decentralised settings; article on 13th July in 360Dx if you have access talking about this and the AIHL and HCV PoCs https://www.360dx.com/point-care-testing/genedrive-expects-ce-ivd-mark-poc-sars-cov-2-test-fall-advances-hearing-loss-hcv#.YQPhqEDTVPY

5/ Military, to US Department of Defence spec (and funded by them). With distributor Mountain Horse; currently appears in US DoD Fiscal Year (FY) 2022 Budget Estimates as far as I can tell for US Navy, Air Force, National Guard. Link courtesy of cwalsh https://comptroller.defense.gov/Portals/45/Documents/defbudget/fy2022/budget_justification/pdfs/02_Procurement/ROC_Vol1_DW_PROC_PB22_Justification_Book_Final.pdf

6/ Looking forward, TB PoC has similar application/market to HCV PoC imo. Again long term. See FIND again https://www.finddx.org/at-risk-populations/

Other/ Currently debt free with known cash burn. Low mcap. Sales or funding required in due course (if it comes to funding at this commercial stage debt financing may

Lol. Jay you've just bought more now you're full of FUD. Don't get disorientated pal

Tidy buy here last thing. Volumes still low across much of the market I'm looking at, roll on

Lol, that's actually quite good allah. See MyLuck, that's how to troll

Don't hurry back MyLuck

Jeez thepunter1, if you'd read his previous post you'd see the context, he believes it will be higher therefore does not wish to sell at a loss now. We know you're just here to prove some sort of point because you told us so, but at least read the posts your trolling.

Rookie, not making a prediction here but to note that that doesn't tell the whole story - they are able to sell to CLIA certified labs in US (as well as of course sell in other regions with CE-mark or approval they're marketing i.e. EU)

Ref BC all depends I suppose on how their sales cycles are going, to which we are at the moment in the dark. We know they like the format of the product as it fits with their workflow and automation goals and is being manufactured by and using tech from another Danaher group co, so if they want to take it further (i.e. diversified or updated tests using the gdr lypholized 1 step format with concurrent benefits) then sure I could see some sort of move eventually. We'll see I guess

Scratch that, @thepunter1 maybe if your only purpose here wasn't QUOTE "I like being able to say I told you so", you might be able to entertain a number of views. As it is you're constrained by your goal/hobby.